Phase III Study of HS-10504 Versus Platinum-Based Doublet Chemotherapy in Patients With C797S+ NSCLC

This is a randomized, controlled, open-label, multicenter Phase III clinical study designed to evaluate the efficacy and safety of oral HS-10504 monotherapy versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC harboring EGFR C797S mutation after failure of EGFR TKI therapy.

NCT Number	NCT07754123
Lead Sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions	Advanced or Metastatic NSCLC
Enrollment	206 participants
Start Date	2026-09-17
Primary Completion	2028-08-31 (estimated)
Study Completion	2031-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-08-10